— Know what they know.
Not Investment Advice

ALGS NASDAQ

Aligos Therapeutics, Inc.
1W: +0.5% 1M: -10.8% 3M: -5.3% YTD: -39.3% 1Y: -46.2% 3Y: -68.8% 5Y: -98.6%
$5.54
+0.04 (+0.73%)
 
Weekly Expected Move ±6.3%
$5 $5 $6 $6 $6
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 37 · $34.3M mcap · 5M float · 2.91% daily turnover · Short 52% of daily vol

Balance Sheet Trends

Total Assets
$89M +26.3% ▲
5Y CAGR: -19.7%
Total Liabilities
$35M -64.7% ▼
5Y CAGR: -5.0%
Shareholders Equity
$54M +284.8% ▲
5Y CAGR: -24.6%
Cash & Investments
$78M +36.7% ▲
5Y CAGR: -20.4%
Total Debt
$5M -37.3% ▼
5Y CAGR: -16.6%
Net Debt
-$13M +54.4% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$187M$81M$136M$37M$18M
Short-Term Investments$4M$44M$0$20M$60M
Cash & ST Investments$191M$126M$136M$57M$78M
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$14M$8M$5M$5M$5M
Total Current Assets$204M$134M$141M$62M$83M
Property, Plant & Equip.$15M$13M$10M$7M$5M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$15M$0$0$0$0
Other Non-Current Assets$866K$634K$625K$627K$715K
Total Non-Current Assets$31M$13M$10M$8M$6M
Total Assets$235M$147M$152M$70M$89M
— Liabilities —
Accounts Payable$3M$5M$3M$3M$4M
Short-Term Debt$0$0$0$0$0
Deferred Revenue$8M$9M$1M$151K$0
Other Current Liabilities$7M$6M$7M$6M$14M
Total Current Liabilities$39M$33M$24M$22M$21M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$133K$0$28M$72M$12M
Total Non-Current Liabilities$12M$10M$36M$79M$15M
Total Liabilities$51M$43M$59M$99M$35M
— Equity —
Common Stock$4K$4K$7K$8K$9K
Retained Earnings-$303M-$399M-$487M-$618M-$642M
Accumulated OCI$452K$401K$545K$451K$468K
Total Stockholders Equity$185M$104M$92M-$29M$54M
Total Liabilities & Equity$235M$147M$152M$70M$89M
— Key Metrics —
Total Debt$14M$13M$11M$8M$5M
Net Debt-$172M-$69M-$125M-$29M-$13M
Total Investments$19M$44M$0$20M$60M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms